Rewalk Robotics Ltd  

(Public, NASDAQ:RWLK)   Watch this stock  
Find more results for RWLK
1.10
0.00 (0.00%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.05 - 1.15
52 week 1.05 - 3.60
Open 1.10
Vol / Avg. 258,494.00/742,774.00
Mkt cap 31.82M
P/E     -
Div/yield     -
EPS -1.59
Shares 28.92M
Beta 0.79
Inst. own 14%
Feb 15, 2018
Q4 2017 Rewalk Robotics Ltd Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 2, 2017
Q3 2017 Rewalk Robotics Ltd Earnings Release
Nov 2, 2017
Q3 2017 Rewalk Robotics Ltd Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -337.53% -553.81%
Operating margin -309.01% -518.67%
EBITD margin - -506.82%
Return on average assets -102.38% -113.38%
Return on average equity -988.75% -222.78%
Employees 94 -
CDP Score - -

Address

3 Hatnufa st. 6th fl., P.O. Box 161
YOKNEAM, 2069203
Israel
+972-4-9590123 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.

Officers and directors

Kevin W. Hershberger Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Ofir Koren Vice President - Research & Development
Age: 46
Bio & Compensation  - Reuters
Jodi Gricci Vice President - Global Marketing and Training
Age: 48
Bio & Compensation  - Reuters
Jeff Dykan Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Larry Jasinski Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Aryeh Dan Director
Age: 57
Bio & Compensation  - Reuters
Yasushi Ichiki Director
Age: 48
Bio & Compensation  - Reuters
Deborah DiSanzo Independent Director
Age: 57
Bio & Compensation  - Reuters
Glenn P. Muir Independent Director
Age: 58
Bio & Compensation  - Reuters
John William Poduska Sr., Ph.D. Independent Director
Age: 78
Bio & Compensation  - Reuters